Download life-sciences-overview

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

The Cancer Genome Atlas wikipedia , lookup

Transcript
Big data and Life Sciences
Guy Coates
Wellcome Trust Sanger Institute
[email protected]
The Sanger Institute
Funded by Wellcome Trust.
• 2nd largest research charity in the world.
• ~700 employees.
• Based in Hinxton Genome Campus,
Cambridge, UK.
Large scale genomic research.
• Sequenced 1/3 of the human genome.
•
(largest single contributor).
Large scale sequencing with an impact
on human and animal health.
Data is freely available.
• Websites, ftp, direct database access,
programmatic APIs.
• Some restrictions for potentially
identifiable data.
My team:
• Scientific computing systems architects.
DNA Sequencing
TCTTTATTTTAGCTGGACCAGACCAATTTTGAGGAAAGGATACAGACAGCGCCTG
AAGGTATGTTCATGTACATTGTTTAGTTGAAGAGAGAAATTCATATTATTAATTA
TGGTGGCTAATGCCTGTAATCCCAACTATTTGGGAGGCCAAGATGAGAGGATTGC
ATAAAAAAGTTAGCTGGGAATGGTAGTGCATGCTTGTATTCCCAGCTACTCAGGAGGCTG
TGCACTCCAGCTTGGGTGACACAG
CAACCCTCTCTCTCTAAAAAAAAAAAAAAAAAGG
AAATAATCAGTTTCCTAAGATTTTTTTCCTGAAAAATACACATTTGGTTTCA
ATGAAGTAAATCG
ATTTGCTTTCAAAACCTTTATATTTGAATACAAATGTACTCC
250 Million * 75-108 Base fragments
Human Genome (3GBases)
~1 TByte / day / machine
Economic Trends:
Cost of sequencing halves every 12
months.
• Wrong side of Moore's Law.
The Human genome project:
• 13 years.
• 23 labs.
• $500 Million.
A Human genome today:
• 3 days.
• 1 machine.
• $8,000.
Trend will continue:
• $1000 genome is probable within 2 years.
•
Informatics not included.
The scary graph
Peak Yearly capillary
sequencing: 30 Gbase
Current weekly sequencing:
7-10 Tbases
Data doubling Time: 4-6
months.
Gen III Sequencers this year?
Sequencing data flow.
Sequencer
Processing/
QC
Comparative
analysis
Archive
Internet
Structured data
(databases)
Unstructured data
(Flat files)
Pbytes!
Raw data
(10 TB)
Sequence
(500GB)
Alignments
(200GB)
Variation data
(1GB)
Feature
(3MB)
A Sequencing Centre Today
CPU
• Generic x86_64 cluster.
•
(16,000 cores)
Storage
• ~1 TB per day per sequencer.
•
•
(15 PB disk)
(Lustre + NFS)
Metadata driven data management
• Only keep our important files.
• Catalogue them, so we can find them!
• Keep the number of copies we want, and no more.
•
(iRODS, in house LIMs).
A solved problem; we know how to do this.
This is not big data
This is not big data either...
Proper Big Data
We want to compute across all the data.
• Sequencing data (of course).
• Patient records, treatment and outcomes.
Why?
• Cancer: tie in genetics, patient outcomes and treatments.
• Pharma: high failure rate due to genetic factors in drug response.
• Infectious disease epidemiology.
• Rare genetic diseases.
Many genetic effects are small
• Million member cohorts to get good signal:noise.
Translation: Genomics of drug
sensitivity in Cancer
BRAF Inhibitors in maligant melanoma
BRAF inhibitor
15 weeks of treatment
Pre-treatment
molecular
diagnostic
BRAF mutation positive
✔
70% response rate vs 10% for standard chemotherapy
Slide from Mathew Garnet (CGP)
Current Data Archives
EBI ERA / NCBI SRA store
results of all sequencing
experiments.
• Public data availability: A good
thing (tm)
• 1.6 Pbases
Problems
• Archives are “dark”.
• You can put data in, but you can't
•
do anything with it.
In order to analyse the data, you
need to download it all.
• 100s of Tbytes
Situation replicated at local
Institute level too.
• eg How does CRI get hold of their
data currently held at Sanger?
The Vision
Global Alliance for sharing genomic and clinical data
• 70 research institutes & hospitals (including Sanger, Broad, EBI, BGI,
Cancer Research UK)
Million cancer genome warehouse
• (UC Berkeley)
To the Cloud!
Institute A
Analysis
pipeline
Data
Analysis
pipeline
Analysis
pipeline
Data
Analysis
pipeline
Data
Data
Institute B
Analysis
pipeline
Data
Data
How do we get there?
Code & Algorithms
Bioinformatics code:
• Integer not FP heavy.
• Single threaded.
• Large memory footprints.
• Interpreted languages.
Not a good fit for future computing architectures.
Expensive to run on public clouds.
• Memory footprint leads to unused cores.
Out of scope for a data talk, but still an important point.
Architectural differences
dynamic nodes
cpu
cpu
Static nodes
cpu
cpu
cpu
cpu
cpu
VS
Fast Network
Global File system
cpu
Slow Network
Object Store
Whose Cloud?
A VM is just a VM, right?
• Clouds are supposed to be
•
programmable.
Nobody wants to re-write a pipeline
when they move clouds.
Storage:
• Posix:
•
(lustre/GPFS/EMC)?
Object:
• Low level: AWS S3, Openstack
SWIFT, Ceph/rados
• High level: Data management
layer (eg iRODS)?
•
Cloud Interoperability?
• Do we need is more standards?!
Pragmatic approach:
• First person to make one that
actually works, wins.
Moving data
Data still has to get from our instruments
to the Cloud.
Good news:
• Lots of products out there for wide area data
movement.
Bad news:
• We are currently using all of them(!)
Network bandwidth still a problem.
• Research institutes have fast data networks.
• What about your GP's surgery?
UDT / UDR
genetorrent
rsync / ssh
Identity Access
Unlikely that data archives are going to
allow anonymous access.
• Who are you?
Federated identify providers.
• Is everyone signed up to the same federation?
• Does it include the right mix of cross-national co-
•
operation?
Does your favourite bit of software support
federated IDs?
Janet Moonshot
The LAW
Legal
• Theory: anonymised data can be stored and
•
accessed without jumping through hoops.
Practice: Risk of re-identification. Becomes
easier the more data you have.
• Medical records are hard to anonymise and
still be useful.
Ethical
• Medical consent process adds more
restrictions above data-protection law.
• Limits data use & access even if
anonymised.
Controlled data access?
• No ad-hoc analysis.
• Access via restricted API only (“trusted
intermediary model”).
Policy development ongoing.
• Cross juristiction for added fun.
Summary
We know where we want to get to.
• No shortage of Vision
There are lots of interesting tools and technologies out
there.
• Getting them to work coherently together will be a challenge.
• Prototyping efforts are underway.
• Need to leverage expertese and experience in other fields.
Not simply technical issues:
• Significant policy issues need to be worked out.
• We have to bring the public along.
Acknowledgements
ISG:
• James Beal
• Helen Brimmer
• Pete Clapham
Global Alliance whitepaper:
http://www.sanger.ac.uk/about/press/assets/130605-white-paper.pdf
Million Cancer Genome Warehouse whitepaper
http://www.eecs.berkeley.edu/Pubs/TechRpts/2012/EECS-2012-211.html